<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198665</url>
  </required_header>
  <id_info>
    <org_study_id>2010-01-001</org_study_id>
    <nct_id>NCT01198665</nct_id>
  </id_info>
  <brief_title>RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas</brief_title>
  <acronym>RADCHOP</acronym>
  <official_title>A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The urgent need for new effective therapy for T-cell lymphoma patients and promising results
      observed so far in trials with RAD001(everolimus, mTOR inhibitor) strongly warrants the
      investigation of RAD001 combined with CHOP as a first-line treatment in peripheral T-cell
      lymphoma patients.

      Thus, we designed a phase I/II study with the combination of RAD001 with CHOP chemotherapy
      for newly diagnosed peripheral T-cell lymphoma patients.

      Phase I

        1. Primary objective

           : To define the maximum tolerable dose

        2. Secondary objective

             -  To evaluate the dose-limiting toxicity

             -  To evaluate the pharmacokinetics of RAD001

             -  Pharmacogenomic profiling

      Phase II

        1. Primary objective

           : To evaluate the overall response rate

        2. Secondary objective

             -  To estimate the time to progression

             -  To estimate overall survival

             -  Pharmacogenomic profiling
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 +
      CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP
      CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W
      100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO
      (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be
      continued until planned 6 cycles or disease progression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determination of the maximum tolerable dose and evaluation of response rate</measure>
    <time_frame>Phase I for maximal tolerable dose and phase II for efficacy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>doe-limiting toxicity and pharmacogenomics</measure>
    <time_frame>Phase I/II</time_frame>
    <description>Phase I
To evaluate the dose-limiting toxicity
To evaluate the pharmacokinetics of RAD001
Pharmacogenomic profiling Phase II
To estimate the time to progression
To estimate overall survival
Pharmacogenomic profiling</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Peripheral T Cell Lymphoma Unspecified</condition>
  <condition>Anaplastic Large Cell Lymphoma, ALK-negative</condition>
  <condition>Angioimmunoblastic T Cell Lymphoma</condition>
  <condition>Cutaneous T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>RAD001-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001 (Everolimus)</intervention_name>
    <description>Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks</description>
    <arm_group_label>RAD001-CHOP</arm_group_label>
    <other_name>Cytoxan, Doxorubicin, Vincristine, prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven peripheral T-cell lymphoma, unspecified, (PTCL), ALK-negative
             anaplastic large cell T-cell lymphoma (ALCL), Angioimmunoblastic T cell lymphoma
             (AITL), Cutaneous T-cell lymphoma

          2. Adequate organ function as defined by the following criteria:

             A.Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT))
             and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤2.5
             x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5
             x ULN if liver function abnormalities are due to underlying malignancy B.Total serum
             bilirubin ≤1.5 x ULN C.Absolute neutrophil count (ANC) ≥1500/µL D.Platelets
             ≥100,000/µL E.Hemoglobin ≥9.0 g/dL (may be transfused or erythropoietin treated)
             F.Serum calcium ≤12.0 mg/dL G.Serum creatinine ≤1.5 x ULN

          3. At least one measurable lesion

          4. ECOG PS 0-2

          5. Informed consent

          6. Age 20 to 70 years old

        Exclusion Criteria:

          1. Prior radiation therapy or surgery within 4 weeks prior to study entry

          2. History of central nervous system (CNS) metastases

          3. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.

          4. Pregnancy or breastfeeding.

          5. Hepatitis B virus surface antigen positive

          6. Extranodal NK/T cell lymphoma

          7. Mycosis fungoides

          8. ALK-positive Anaplastic large cell lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyoungki-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Medical Center, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>March 1, 2015</last_update_submitted>
  <last_update_submitted_qc>March 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kim, Seok Jin</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>RAD001</keyword>
  <keyword>chemotherpy</keyword>
  <keyword>T cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

